💊 Health Futures #38

Happy Monday 👋

This week, ZEISS Medical Technology, a technology enterprise operating in the optics and optoelectronics industries, launched the KINEVO 900 S, which is designed for neurosurgery. Olympus Corporation launched VISERA S, and Olympus plans to launch VISERA S in Europe, parts of Asia, and Oceania. In the pharmaceuticals sector, Acumen Pharmaceuticals extended its partnership with Lonza, where Lonza will manufacture its monoclonal antibody. Meanwhile, Bristol Myers Squibb agreed to a research and licensing deal with Prime Medicine in the biotech field. Within health deals, Kailera Therapeutics raised $400M in Series A funding round.

💻 Health Hardware and Devices

🤖 ZEISS Medical Technology launched the KINEVO 900 S, a new Robotic Visualization System.  The KINEVO 900 S is designed for neurosurgery and other surgical disciplines and offers features such as digital visualization, collaborative assistant functions, and connected intelligence.

🏥 Intuitive, a pioneer of robotic-assisted surgery, expanded its European headquarters in Switzerland. This expansion reflects Intuitive's commitment to its growth in Europe and its focus on creating a fulfilling workplace for its employees.

🩻 Olympus Corporation announced the launch of VISERA S. VISERA S, an all-in-one imaging platform with stroboscopy designed to improve ENT diagnostic efficiency and patient experience. 

💊 Pharmaceuticals

🩹 Acumen Pharmaceuticals extended its partnership with Lonza. The partnership aimed to enable the potential future commercial launch of its monoclonal antibody.

🎗️ Roche to acquire two experimental breast cancer drugs from Regor Therapeutics for $850M.  The drugs are being developed as next-generation CDK inhibitors, where one of its candidates has shown promising results in early-stage trials.

🩺 Nxera Pharma partners with Shionogi to distribute and sell Quviviq in Japan. Quviviq secured approval for an insomnia drug in Japan, and this partnership will allow Shionogi to handle the distribution and sales of Quviviq solely in the Japanese market.

🧬 Biotechnology

🔬 Bristol Myers Squibb agreed to a research and licensing deal with Prime Medicine.  The deal allows the development of ex vivo T-cell therapies. Prime Medicine will design gene editing reagents based on its PASSIGE technology, and BMS will take these to develop ex vivo T-cell therapies.

🩸CSL Behring received a positive recommendation from the Spanish Interministerial Commission on the Pricing of Medicines (CIPM). Hemgenix is a one-time gene therapy approved for adults with severe and moderately severe hemophilia B.

🧪 The number of clinical trials of new drugs in Russia has decreased by 26.4% year-on-year. This decline is likely due to reduced investment activities in the local pharmaceutical market. 

💰 Deals of the Week

🧫 Kailera Therapeutics raised $400M in a Series A funding round. The company plans to use the funds to grow and develop its business.

🔬 Aktis Oncology, a clinical-stage biotechnology company, closed a $175M Series B financing.  The funds will help advance its differentiated radiopharmaceuticals pipeline.

🧪 Mirai Bio, a MA-based bioplatform innovation company, raised $50M. The funds will be used to advance its platform for genetic medicine development across a wide range of therapeutic areas and modalities.

💻 Nym, a NYC-based leader in autonomous medical coding, secured $47M in growth funding.

🩺 Air Doctor, which specializes in travel health, raised $20M in Series B funding. The funds will accelerate its ongoing expansion in Asia, further consolidating its position as a global market player in travel health.

Thank you for reading. Have a great week ahead!
Have some feedback or suggestions? Let us know at hello@holoniq.com